- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- Erlotinib, Erlotinib plus sulindac, Placebo
- Drug
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2014
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 54
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- placebo, BIBW 2992
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 585 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 14
- States / cities
- Kingman, Arizona • Fayetteville, Arkansas • Anaheim, California + 11 more
- Conditions
- Pancreatic Cancer
- Interventions
- LY2495655, Placebo, Standard of Care Chemotherapy
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 5
- States / cities
- Washington D.C., District of Columbia • Dallas, Texas • The Woodlands, Texas + 2 more
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- HS110 vaccine, Placebo
- Biological
- Lead sponsor
- Heat Biologics
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- Interventions
- erlotinib, onartuzumab, placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 15
- States / cities
- Bakersfield, California • Fullerton, California • Long Beach, California + 11 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Dacomitinib (PF-00299804), Active Comparator (erlotinib), Placebo erlotinib, Placebo PF00299804
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 878 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 107
- States / cities
- Birmingham, Alabama • Florence, Alabama • Mobile, Alabama + 65 more
- Conditions
- Dermatologic Complications, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- sunscreen, placebo
- Drug · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 208
- States / cities
- Jacksonville, Florida • Aurora, Illinois • Bloomington, Illinois + 130 more
- Conditions
- Bladder Cancer
- Interventions
- Polyphenon E, erlotinib hydrochloride, Erlotinib placebo, Polyphenon E
- Dietary Supplement · Drug · Other
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 5
- States / cities
- Phoenix, Arizona • Los Angeles, California • Santa Monica, California + 1 more
- Conditions
- Pancreatic Cancer
- Interventions
- placebo + gemcitabine + erlotinib, Placebo + gemcitabine, calcitriol + gemcitabine, calcitriol + gemcitabine + erlotinib
- Drug
- Lead sponsor
- Novacea
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Lung Cancer, Non-small Cell Lung Cancer
- Interventions
- Patritumab, Erlotinib, Placebo
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 20 Years and older
- Enrollment
- 145 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 26
- States / cities
- Glendale, Arizona • Duarte, California • La Verne, California + 23 more
- Conditions
- Non-Small Cell Lung Cancer (NSCLC) With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy
- Interventions
- OSI-906, erlotinib, placebo
- Drug
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 205 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 7
- States / cities
- Jacksonville, Florida • Port Saint Lucie, Florida • Albany, Georgia + 4 more
- Conditions
- Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
- Interventions
- AZD9291 80 mg/40 mg + placebo, Placebo Erlotinib 150/100mg, Placebo Gefitinib 250 mg, Erlotinib 150/100 mg, Gefitinib 250 mg, Placebo AZD9291 80 mg/ 40 mg
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 674 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2025
- U.S. locations
- 14
- States / cities
- Anaheim, California • Santa Rosa, California • West Hills, California + 10 more
- Conditions
- Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Cancer AJCC v8
- Interventions
- Biospecimen Collection, Carboplatin, Cisplatin, Clinical Observation, Computed Tomography, Crizotinib, Cytology Specimen Collection Procedure, Echocardiography Test, Erlotinib, Gemcitabine Hydrochloride, Nivolumab, Paclitaxel, Pembrolizumab, Pemetrexed, Pemetrexed Disodium, Placebo Administration, Positron Emission Tomography
- Procedure · Drug · Other + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 7,458 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2027
- U.S. locations
- 1655
- States / cities
- Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 1013 more
- Conditions
- Pancreatic Cancer
- Interventions
- erlotinib hydrochloride, gemcitabine hydrochloride
- Drug
- Lead sponsor
- NCIC Clinical Trials Group
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 569 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2009
- U.S. locations
- 74
- States / cities
- Tucson, Arizona • Springdale, Arkansas • Berkeley, California + 63 more
- Conditions
- NSCLC, Non Small Cell Lung Cancer
- Interventions
- OSI-906, Erlotinib, Placebo
- Drug
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 13
- States / cities
- La Jolla, California • Tampa, Florida • Weston, Florida + 8 more
- Conditions
- Recurrent Skin Cancer, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Squamous Cell Carcinoma of the Skin, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity
- Interventions
- erlotinib hydrochloride, linsitinib, placebo, radiation therapy, therapeutic conventional surgery, laboratory biomarker analysis
- Drug · Radiation · Procedure + 1 more
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Cirrhosis, Liver, Advanced Liver Fibrosis
- Interventions
- erlotinib hydrochloride, Placebo
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Interventions
- erlotinib hydrochloride, paclitaxel, carboplatin, bevacizumab
- Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 108
- States / cities
- Aurora, Colorado • Boulder, Colorado • Colorado Springs, Colorado + 65 more
- Conditions
- Psoriasis
- Interventions
- erlotinib, placebo tablet
- Drug · Other
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Head and Neck Cancer, Non Small Cell Lung Cancer
- Interventions
- Erlotinib, Dasatinib + Placebo, Erlotinib plus Dasatinib, Placebo
- Drug
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- bevacizumab, placebo, erlotinib HCl
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,145 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2014
- U.S. locations
- 177
- States / cities
- Mobile, Alabama • Fort Smith, Arizona • Scottsdale, Arizona + 160 more
- Conditions
- Metastatic Squamous Cell Carcinoma of the Hypopharynx, Metastatic Squamous Cell Carcinoma of the Larynx, Metastatic Squamous Cell Carcinoma of the Oral Cavity, Metastatic Squamous Cell Carcinoma of the Oropharynx, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVC Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVC Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVC Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVC Oropharyngeal Squamous Cell Carcinoma AJCC v7
- Interventions
- Carboplatin, Cisplatin, Docetaxel, Erlotinib Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study, Placebo, Quality-of-Life Assessment
- Drug · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2020
- U.S. locations
- 5
- States / cities
- Houston, Texas • Nassau Bay, Texas • Sugar Land, Texas + 1 more
- Conditions
- Metastatic Non-Small Cell Lung Cancer
- Interventions
- Ramucirumab, Placebo, Erlotinib, Gefitinib, Osimertinib
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 545 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2026
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Denver, Colorado • Honolulu, Hawaii + 4 more
- Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Interventions
- U3-1287, Erlotinib, Placebo
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 222 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 14
- States / cities
- Glendale, Arizona • Scottsdale, Arizona • Anaheim, California + 11 more